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Abstract
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a dietary polyphenolic phytochemical that has demonstrated
health benefits such as cardioprotection, the prevention of neurodegeneration and chemoprevention. Resveratrol
has shown great potential in the prevention and treatment of carcinomas and clinical trials support resveratrol as
anticancer compound in colorectal carcinoma. Colorectal cancer remains a major cause of cancer-related deaths for
both men and women in industrialized countries. Because of this widespread prevalence, identifying major risk
factors and initiating colorectal screening procedures provide the distinct advantage for recognizing early disease
and addressing treatable forms of CRC. Epidemiological studies of fruit and vegetable consumption in relationship to
developing CRC have led to the notion that safe and inexpensive chemopreventive agents might be a valuable tool
in diminishing the morbidity and mortality of CRC. While clinical trials and in vivo data show positive effects of
resveratrol in CRC, the mechanism of action is relatively unclear. In this review, we will evaluate the current literature
on the actions of resveratrol in CRC and provide a more mechanistic view of resveratrol in relationship with CRC.

List of Abbreviations:
CRC: Colorectal Carcinoma; CIN: Chromosome Instability; MSI:
Microsatellite Instability; CIMP: CpG Island Methylator Phenotype;
FAP: Familial Adenomatous Polyposis, HNPCC: Hereditary
Nonpolyposis Colorectal Cancer; APC: Adenomatous Polyposis Coli;
MMR: Mismatch Repair; ACF: Aberrant Crypt Foci
Keywords: Resveratrol; CRC; Colorectal cancer

Introduction

cancer prevention, safe and inexpensive chemopreventive agents are
being developed that exhibit great value in diminishing the morbidity
and mortality of CRC. Enthusiasm for this approach is based on
epidemiological studies of fruit and vegetable consumption, and
reduction in risk for CRC [8,9], combined with animal investigations
that examined dietary phytochemicals in CRC prevention.
Resveratrol has been characterized as a pleiotropic agent that
exhibits multiple targets in cancer cells with marginal effects on nonmitotic cells [10-12]. Included among the responsive cellular processes
are cell cycle checkpoints, apoptotic and angiogenic pathways, host
immune responses, and genomic instability. Since resveratrol may have
multiple actions in diseased tissue [13,14], it is important to evaluate
the effectiveness of resveratrol in CRC. In this review we summarize
the recent literature to assess the mechanisms of actions of resveratrol
in CRC.

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a natural
polyphenol that can be found in several nutritional sources, including
grape skin, peanuts and berries. Resveratrol was first identified by
Michio Takaoka in 1940 in Veratrum grandiflorum O. Loes [1] and
was hypothesized in 1992 to be responsible for the cardioprotective
effects of red wine [2]. However, resveratrol became of major interest
to the scientific community after a study of Pezzuto et al., who showed
that resveratrol interfered with the initiation of 7,12dimethylbenzanthracene (DMBA)-induced skin cancer and
progression of breast cancer in mice [3]. Many publications have since
followed and provide evidence that resveratrol exhibits various
beneficial health effects, such as cardiovascular protection [4] and
chemoprevention [5]. The use of resveratrol for the treatment of CRC
seems to be of most current interest; two completed clinical studies
have shown direct positive changes in colorectal tissues after oral
resveratrol intake [6,7].

The role of nutrition in cancer prevention is well supported by
animal studies and clinical trials as well as epidemiological findings.
Chemoprevention is based on the general concept that naturallyoccurring plant or animal substances and even synthetically produced
derivatives can prevent, suppress, or reverse carcinogenic progression
to metastatic disease. The importance of the effect of diet on cancer
prevention and control is evidenced by the fact that approximately 274
clinical trials in the USA have recently been completed or are currently
ongoing (clinicaltrials.gov: accessed on May 5th, 2016).

Colorectal cancer (CRC) is a major cause of cancer-related deaths
for both men and women living in industrialized countries. Because of
this widespread prevalence, identifying major risk factors and
initiating colorectal screening procedures provide the distinct
advantage for recognizing early disease and addressing treatable forms
of CRC. While CRC screening procedures have the highest impact for

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a polyphenolic
phyloalexin present in over 70 plant species and found in particular
within the skin or peel of grapes, peanuts and berries [15,16]. Its
pleiotropic properties have been observed in a wide variety of cancers
including breast, prostate, lung, skin, and colon and of the nine clinical
chemoprevention trials; six involve resveratrol and GI cancers. The
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flurry of recent research activities on resveratrol largely stems from the
seminal report by Pezzuto et al. in 1997, showing its anticancer
properties [3].
The anti-tumorigenic activity of resveratrol is supported by in vitro
studies [17,18], animal experiments [10,19], and clinical trials [20-23].
Patients diagnosed with CRC and fed resveratrol show statistically
significant reductions in tumor proliferation [6,7]. This effect correlates
with HPLC/UV/Mass Spectrometry-validated increases in resveratrol
and its metabolites in resected colorectal tissues and suggests that,
unlike cells located within internal organs, resveratrol metabolites can
reach sufficiently high, anti-carcinogenic levels in responsive target
cells within the gastrointestinal tract [6,24].

Bioavailability of resveratrol
One of the major limitations encountered in studies on resveratrol is
its availability in humans. This is related to high resveratrol excretion
rates in intestinal cells and the various resveratrol modifications that
occur after resveratrol uptake into intestinal cells.
Resveratrol uptake and transport: Mechanisms of resveratrol uptake
following oral ingestion have not been completely elucidated. Several
in vitro, ex vivo and in vivo studies have suggested that a passive
uptake and an active extrusion process are responsible for resveratrol
uptake and excretion in the intestine. Cell culture studies using Caco-2
cells show that trans-resveratrol diffuses into enterocytes and that
trans-resveratrol is actively transported by the sodium-glucose linked
transporter (SGLT1) [25]. Subsequent studies show that transresveratrol can also be transported via clathrin-independent
endocytosis [26].

Ex vivo studies, that use organ perfusion techniques, and in vivo
studies using rats have shown that resveratrol can be passively
absorbed and conjugated with glucuronic acid or sulfate to form
resveratrol glucuronide or resveratrol sulfate [27,28]. These conjugates
are formed by UDP-glucuronosyltransferases (UGT) and
sulfotransferases (SULT), respectively [29], which convert resveratrol
to hydrophilic derivatives, and facilitate renal and biliary secretion. In
rats, a large fraction of these metabolites undergo enterohepatic
circulation which can reintroduce as much as 50% of the initial
amount of resveratrol absorbed [29]. Extrusion of resveratrol
glucuronide and, to a lesser extent, resveratrol sulfate into the intestinal
lumen is mediated by three ABC-transporters: P-glycoprotein (P-gp/
ABCB1), multidrug resistance-associated protein 2 (MRP2/ABCC)
and the breast cancer resistance protein (BCRP/ABCG2) [29,30].
Residual intracellular resveratrol glucuronide is released through the
serosa into the bloodstream by another multidrug resistanceassociated protein 3 (MRP3). MRP3 is an ABC-transporter that
transports resveratrol and other polyphenolic compounds as well
riboflavin and biotin into the bloodstream [31]. Once in the blood,
resveratrol can be transported as the glucuronide bound to albumin
[26,32].
Notably, these transporters and modifying enzymes are differently
distributed along the intestinal tract, but expression is also slightly
dependent on the individual. Data, mostly obtained by studies in rat
intestine, suggest that MRP2 and ABCG2 transporters are mainly
expressed in the duodenum and jejunum, and gradually decrease
further down the intestinal tract [33,34]. By contrast, ABCB1
expression is low in the initial parts of the intestine, but higher in the
ileum and colon. The expression of MRP3 is high in duodenum and
colon, and lower in all other parts of the intestine [35]. UGT proteins
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are abundantly expressed throughout the entire intestine, but are most
prominent in the duodenum and jejunum, after which they gradually
decrease in abundance towards the rectum. The expression of UGT is
both constitutive and inducible, where the level of induction is highly
variable in different parts of the intestine, but also in different
individuals [36]. SULT have several isoforms of which the distribution
is not as clearly identified as the transporters and enzymes described
above. Several SULT isoforms are expressed in the human intestine.
SULT1B1 seems to be the most abundantly expressed isoform in the
small intestine, followed by SULT1A3 and SULT1A1 [37]. Aside from
the many isoforms that exist, quantification of SULT activity is
complicated by the existence of several SULT polymorphisms.
Polymorphisms in e.g. SULTA1 have been shown to exhibit different
enzyme kinetics towards resveratrol metabolites [38].
These studies imply that resveratrol uptake and metabolism in the
intestine is regionally- and individually-specific. The relatively high
concentration of UGT, MRP2 and ABCG2 in the initial parts of the
intestine, (duodenum and jejunum) might form a first line of defense
against ingested xenobiotic compounds, while the presence of MRP3 in
later portions of the intestine (ileum and colon) may ensure the
absorption of specific nutrients and beneficial compounds. This
hypothesis is important in determining the efficacy of resveratrol in
ameliorating intestinal carcinomas. When considering dietary intake,
the duodenum and jejunum probably receive the highest concentration
of unmodified resveratrol, but modify and excrete resveratrol soon
after it enters the cell, due to the high activity of UGT, MRP2 and
ABCG2, aka BCRP. By contrast, regions in the ileum and colon may be
subject to less unmodified metabolites, but also contain less
metabolizing enzymes, which could make these regions more
responsive to resveratrol supplementation. Other factors that influence
the availability of resveratrol may involve the distribution, titer, and
types of microbial flora along the GI tract.
Bioactivity of resveratrol: Different studies in healthy volunteers
have examined the bioavailability of resveratrol after oral and
intravenous administration. Generally, peak levels of resveratrol are
observed after 0.5 to 1.5 hours following ingestion. Due to use of
different resveratrol doses, peak plasma levels of resveratrol have been
reported to vary from 3.89 μg/L to 750 μg/L [39-43]. Two studies
reported similar peak serum concentration around 470-490 μg/L after
25 mg/70 kg intake resveratrol [41,42]. The major metabolites
observed were conjugated forms of resveratrol. While some studies
reported small amounts of unmodified resveratrol [39,42], others
found no traces of unmodified resveratrol in the plasma [41]. Halflives of resveratrol per se were found to be short. Resveratrol is
excreted within 12-24 hours post oral administration. One study
reported that the amount of resveratrol found in urine after 12h of
ingestion was as high as 85% of the ingested dose [41].
Interestingly, two studies reported that intakes of higher doses of
resveratrol lead to smaller fractions of excreted resveratrol compared
to low-dose administration. Meng et al. [43] found that ingestion of
0.03 and 1 mg/kg body weight resveratrol in two subjects resulted in
recovery of 52% and 26% of the administered dose in urine after 24
hours, respectively. Similarly, Boocock et al. [39] reported that while
approximately 20% resveratrol was excreted at a dose of 0.5 gram, less
than 10% was excreted at a dose of 5 gram resveratrol. Additionally,
even though the half-life of total resveratrol varied greatly among
individuals, the half-life of intravenously administered resveratrol was
approximately an hour longer than orally administered resveratrol
[41].
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Although differences were small, absorption of resveratrol was
greater when given in grape juice, compared to white wine or vegetable
juice [42]. It has been hypothesized that resveratrol uptake may
depend on the presence of other dietary factors. For example, the
bioavailability of resveratrol is increased by combining its intake with
piperine, a compound abundant in black pepper, which inhibits several
ABC transporters, including resveratrol-excreting ABCB1, MRP2 and
ABCG2 [44-46]. This hypothesis was further supported by the
observation that resveratrol pharmacokinetics show a circadian
rhythm, where resveratrol bioavailability was highest in the morning
[40]. Presumably, the digestion or presence of other foods could
interfere with the bioavailability of resveratrol, which is prevalent
during the day, but of less importance after a night of fasting.
Bioactivity of resveratrol conjugates: Since the availability of
unmodified resveratrol is low in humans, it has been hypothesized that
resveratrol conjugates could have biological functions similar to those
of the parent compound. There are some indications in the literature
which support this hypothesis. In an in vitro experiment, using
fibroblasts from patients with an inborn enzyme deficiency of
mitochondrial fatty acid beta-oxidation, it has been shown that cisresveratrol, trans-picied and dihydroresveratrol improved fatty acid
oxidation [47], potentially through stimulating mitochondrial
biogenesis or via competition for cellular extrusion of riboflavin, which
is the precursor for mitochondrial FAD, the coenzyme of acyl-CoA
dehydrogenases critical for fatty acid β-oxidation [48]. However, the
effects of major resveratrol metabolites – resveratrol-3-O-glucuronide,
resveratrol-4-O-glucuronide and resveratrol-3-O-sulfate – on fatty
acid oxidation was modest to non-existent [47]. Another study
evaluated the biological activities of five resveratrol sulfate metabolites
in several in vitro assay systems. Even though two of these metabolites
showed induction of NADPH:quinone oxidoreductase 1 (NQO1),
inhibition of COX-1 and COX-2, and decrease in NO production in a
cell-free system, cellular uptake of these resveratrol metabolites was
insignificant in vitro [49]. A large study, also using various in
vitro assays, tested 92 resveratrol derivatives and reported that several
metabolites had activities that were even more potent than the parent
compound in specific assays. However, it should be noted that
resveratrol-glucuronide was not included and that only one resveratrol
sulfate metabolite was tested [50].
It has also been proposed that sulfated metabolites of resveratrol
provide an intra-cellular pool of resveratrol that can be accessed by
desulfation. Additionally, although resveratrol-glucuronide does not
seem to exhibit effects on CRC cell proliferation, resveratrol-sulfate is
able to inhibit CRC cell proliferation by 20% in vitro, while having no
effect on normal epithelium-derived colorectal cells. The desulfation of
resveratrol was confirmed in mice: hydrolysis of the sulfate group
yielded free resveratrol which accounted for 2% of the total resveratrol
content in the plasma. The concentration of resveratrol-sulfate on the
serosal side of the human intestine can reach approximately 640 μM,
which is much higher than the concentration used in the in vitro
experiments that showed a reduction in proliferation of 20% [24].
Through these findings, one may hypothesize that the observed
beneficial effects of resveratrol in reducing CRC proliferation is
mediated partially through resveratrol sulfate and partially through
desulfation events, which yield the parent compound.
All in all, it seems that concentrations of unmodified resveratrol
available following oral ingestion are much less than those used in
experimental studies. However, since the intestinal tract is directly
exposed to resveratrol from the diet, gastrointestinal cells may be
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exposed to concentrations much higher than observed plasma levels,
as found by Patel et al. Additionally, one of the major resveratrol
derivatives, resveratrol sulfate, seems to exert activities in colorectal
tissue. These findings support the use of resveratrol in the treatment of
intestinal diseases and may contribute to the observed amelioration of
CRC after resveratrol supplementation [6,7]. Resected colorectal tissue
indeed contains traces of resveratrol and its metabolites, suggesting
that, unlike cells located within internal organs, resveratrol metabolites
can reach sufficiently high, anti-carcinogenic levels in responsive target
cells within the gastrointestinal tract [6,24].

Colorectal carcinoma (CRC)
CRC is the third and second most common cancer in males and
females worldwide, respectively. Over the past few decades, a decline in
mortality (2.5%) and incidence rate (4.3% among adults 50 years of age
or older) has been observed in CRC; nevertheless, this disease remains
a major contributor to cancer cases and was the second leading cause
of cancer-related deaths in 2015 (8.4%) for both men and women, after
lung carcinoma.
The GI tract is highly predisposed to developing cancerous lesions,
partly because of rapid epithelial cell turnover and exposure to dietary
toxins. Not surprisingly, adenoma formation is not uncommon in
individuals younger than 50 years of age. Colorectal screening reveals
that 12% of women and 24% of men develop adenomas. In women and
men 80 years and older, formation rates of adenomas increase to 27%
and 40%, respectively [51]. Progression of CRC from adenoma to
carcinoma originates over an extended period of time within a colony
of progenitor cells. The etiology of disease progression is thought to be
heterogeneous characterized by unique genomic abnormalities,
molecular changes, and distinct pathological profiles [52,53].

In vivo evidence for chemoprevention of CRC
Different animal models have been used in the evaluation of
resveratrol supplementation on CRC. Using mouse models of CRC,
investigators have reported different outcomes with resveratrol. In a
mouse model of KRAS-activated sporadic CRC, Saud et al. showed
that resveratrol prevented tumorogenesis by inhibiting KRAS
expression. In a study using five week old mice consuming drinking
water with 0.01% resveratrol, Schneider at al. showed that cyclin D1
and D2 expression decreased in CRC tissue and that there was 70%
reduction in small intestinal tumors. However, resveratrol
supplementation in the form of 4, 20 or 90 mg/kg body weight in the
diet failed to show effects on CRC tumorigenesis in 43 day old mice
[54]. Additionally, Sale et al. found a reduction in the number of
colorectal adenomas at a dose of 240 mg/kg body weight resveratrol in
4 week old mice, but did not find any significant reductions in
adenoma number at a dose of 60 mg/kg body weight resveratrol. These
differences in findings may be due to the method of dosing, e.g.
injection vs. diet exposure in the drinking water.
Several in vivo studies in rats, with varying protocols, have shown
that resveratrol reduces the manifestation of aberrant crypt focus
(ACF), which are early precursors of CRC, compared to control rats
[55-57]. Also in rats, Tessitore et al. reported an increase in expression
of BAX, a pro-apoptotic protein, in CRC tissue after resveratrol
supplementation, which suggests activation of apoptosis in CRC after
resveratrol supplementation. This hypothesis is further supported by
the finding that resveratrol increases the expression of activated
caspase-3, a central player in the activation of apoptosis, in CRC in rats
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[58]. Thus, mouse and rat models seem to support the claim that
resveratrol has beneficial effects in the prevention and reduction of
CRC lesions.

Molecular targets of resveratrol
Inflammatory factors: Persuasive lines of evidence indicate that
expression of proinflammatory mediators correlate with progression of
cancer [59]. At the molecular level, inflammation can be measured by
the expression of inflammatory transcription factors (e.g., NF-κB,
AP-1, STAT3), inflammatory enzymes (e.g., COX2, MMP-9, PPAR),
inflammatory cytokines (e.g., IL-6, IL-8, and TNF-α), and chemokines
(CCL3, CCL4, CCL5) [60]. Because of its pleiotropic activity,
resveratrol is able to suppress or to interfere with these key
inflammatory molecular targets almost instantly [61]. In addition,
recent interest in resveratrol has focused on its ability for modulation
of tumor-suppressive miRNA by inducing apoptotic cell death [62,63].
In absence of a clear mechanistic link, the activity of resveratrol may be
partially dependent upon an impaired expression of certain miRNAs
associated with inflammatory and tumor suppression effects
(miR-663), proinflammatory effects (miR-155), or oncogenicity (miR
-21).
This role of resveratrol in inflammation is especially important to
CRC, since inflammation has been linked to the development of CRC.
This is especially visible in inflammatory bowel diseases (IBD),
including Crohn disease and ulcerative colitis, which pose a significant
increase in risk for CRC. Patients diagnosed with IBD below the age of
30 exhibit a 4 times higher risk to develop CRC than are patients
diagnosed at a later age [64]. The modulation of inflammatory agents
by resveratrol may therefore reduce the risk of developing CRC and
resveratrol potentially acts as a chemopreventive agent.
Antioxidants and phase II detoxification: Detoxifying enzymes are
extremely important in cancer prevention. Each individual is exposed
to many potential carcinogens every day, most of which undergo
oxidative metabolism by detoxifying enzymes. Phase I enzymes, such
as the cytochrome P450 (CYP) family, form a first-line defense towards
eliminating toxic substances and produce products that are eliminated
though conjugation reactions by phase II enzymes, exemplified by
glutathione S-transferase (GST), NQO1 and heme oxygenase-1
(HO-1). However, pro-carcinogenic substances can also be activated by
phase I enzymes. This occurs for example during the processing of
polycyclic aromatic hydrocarbons (PAH). Resveratrol has been shown
to reduce this unfavorable activation by inhibiting CYPA1, an enzyme
involved in metabolic activation, in human mammary epithelial cells
[65], human hepatoma cells and human mammary carcinoma cells
[66]. Aside from affecting selectively phase I enzymes, resveratrol also
stimulates the expression and activity of phase II enzymes.
Supplementation of resveratrol in the medium of different cell types
resulted in increased expression and activation of NQO1 [67],
increased HO-1 expression and increased cellular glutathione content
[68,69].
Intestinal cells are constantly exposed to toxic substances that are
ingested through food. The constant renewal of the intestinal
epithelium prevents these toxic compounds from having a permanent
effect. However, intestinal stem cells are permanent residents of the
intestine and need to prevent the accumulation of toxic substances.
Thus the stimulation of the detoxification of toxic substances by
resveratrol is another potential mechanism by which resveratrol exerts
its chemopreventive actions.
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Cell cycle: Failure to undergo cell cycle arrest is one of the hallmarks
of cancer. Resveratrol has been shown to elicit cell cycle arrest in
various types of cancer. For example, in a cellular model system of
hepatocellular carcinoma, HepG2 cells, resveratrol induces cell cycle
arrest in G1 and G2/M [70]. In a different hepatoma model system,
Huh-7 cells, resveratrol induced cell cycle arrest, which was manifested
through inhibition of cyclin E, cyclin A, and cyclin-dependent kinase
(CDK)-2 [71]. Other model systems for cancer have also shown
resveratrol-induced cell cycle arrest. Cell lines representing lung cancer
were arrested in G0/G1, potentially through down-regulation of cyclin
D1, CDK4 and CDK6, accompanied by the up-regulation of CDK
inhibitors, p21 and p27 [72]. Studies in prostate cell lines reported cell
cycle arrest at the G0/G1 phase through down-regulation of cyclins
and CDKs and upregulation of CDK inhibitors [73].
As for any cancer, the inhibition of the cell cycle in CRC will slow
lesions that have formed already and may cause cell cycle arrest in
precancerous cells, preventing further progression. Since CRC
develops through an extended process of acquiring mutations,
interventions in successive steps of CRC formation may prevent lesions
to reach the final steps of tumor formation. The literature is replete
with studies providing evidence for the inhibitory effects of resveratrol
at several phases of the cell cycle, supporting this additional aspect in
the chemopreventive effects of resveratrol in CRC.
Angiogenesis and metastasis: As carcinomas grow, a hypoxic
environment often arises within the center of the tumor because of
increased metabolic activities and an increased requirement for
molecular oxygen. To maintain a viable milieu, tumor cells overexpress
hypoxia inducible factor (HIF), which acts as a regulator of cellular
oxygen homeostasis by inducing the transcription of several hypoxiaresponsive genes. Factors that are synthesized as a result include
vascular endothelial growth factor (VEGF), iNOS and erythropoietin.
Consequently, angiogenesis will enable tumor cells to continue to grow
and potentially invade other tissues. Resveratrol disables this
mechanism by blocking expression of HIF-1α and VEGF [74,75]. In a
manner similar to that seen in inflammation, resveratrol inhibits iNOS
in these cell lines as well.
Metastasis is a central mechanism to tumor progression, which
often limits treatment options and reduces survival rate. Therefore,
prevention of metastatic events would greatly improve chances of
survival. It has been shown that resveratrol is capable of inhibiting
mediators of metastasis, which are believed to include
lysophosphatidic acid (LPA), transforming growth factor (TGF) and
focal adhesion kinase (FAK). LPA induces the expression of e.g.
HIF-1α and VEGF, and promotes cell migration. These events were
efficiently blocked by resveratrol in a human ovarian carcinoma cell
line [76]. Additionally, the induction of cell adhesion, migration and
invasion of lung cancer cells, mediated by TGF-β1, was also greatly
inhibited by resveratrol in A549 lung cancer cells [77].
As for other carciomas, angiogenesis and metastasis are pertinent to
CRC as well, since CRC often metastasizes to the liver through the
portal vein. Metastasis to the liver is found in 10-25% of CRC patients
who have surgery for CRC [78]. Prevention of metastases and larger
tumor masses in CRC are a valuable treatment option, since smaller
CRC lesions can be dissected surgically, resulting in a 5-year survival
rate of 90%. However, CRC that is detected at more advanced stages
have survival rates ranging from 13-71% after 5 years. Unfortunately,
only 40% of CRC cases are diagnosed at early localized stages, reducing
the total survival rate significantly [79]. Thus, by decreasing
angiogenesis and metastasis, resveratrol could increase the amount of
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patients that develop CRC to a localized stage, resulting in higher
overall survival rates for CRC.

Future perspectives
In this review we have evaluated the current literature on the actions
of resveratrol in CRC. Various reports support the notion that
resveratrol is a potential natural compound that has anticancer
properties in CRC. Mechanistically, several molecular targets have
been proposed, including those involved in inflammation,
detoxification, cell cycle and angiogenesis.
However, it is generally known that CRC evolves through distinct
etiologies. Three genetic profiles, namely chromosome instability
(CIN), CpG island methylator (CIMP) and microsatellite instability
(MSI), are discriminated; each with distinct and significant
contribution to the development of CRC. Although a distinction
between different etiologies is useful in assessing treatment options
[80,81], few reports focus on the potential different actions of
resveratrol in these defined etiologies. Resveratrol might affect each
etiology differently, potentially doing more harm than good in certain
etiologies. Therefore, we proposed that future research evaluate
resveratrol in the light of the aforementioned CRC etiologies. As a first
step in this process, we have included data on the distinction of CRC
etiologies in CRC (Figure 1).

Figure 1: Graphical representation of CRC etiologies. The three
major CRC etiologies are CIN, CIMP and MSI. Each etiology is
characterized by several mutations, which are depicted at the
borders of each etiology. The prevalence of each CRC etiology [82]
is enclosed in boxes; the CIMP and MSI etiology frequently overlap
[83].
The chromosome instability (CIN) pathway: The CIN pathway is
regarded as the ‘traditional’ or ‘suppressor’ pathway in CRC
progression; an estimated 80% of CRCs develop via the CIN pathway
[84]. Appearance of a dysplastic ACF, a mucosal lesion that precedes
the development of a polyp [85] is the earliest identifiable lesion in the
CIN pathway. Among the initial events in the CIN pathway leading to
CRC are the mutations in the adenomatous polyposis coli (APC) gene
and/or loss of chromosome 5q, loss of chromosome 18q and deletion
of chromosome 17p, which contains the important tumor suppressor
gene P53 [84]. Other frequently found mutations in CIN include those
in KRAS, P53, SMAD4 and PIK3CA [86]. However, only a very small
portion of CRC patients display all of these alterations concurrently
[87].
The microsatellite instability (MSI) pathway: The MSI pathway is
characterized by alterations in the MMR system, which can lead to
failure of normal surveillance and post-replication DNA repair [88].
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Impairment of the MSI pathway can result in accumulation of
mutations and potentially, genomic instability. Deficiency in the MMR
also implicates deficiency in repairing errors in microsatellite DNA
replication [89], mediated by DNA polymerases δ and ε [90,91].
Several modifications in microsatellites are observed within CRC
implicated genes; e.g. Transforming Growth Factor, Beta Receptor II
(TGFRII) [92], Bax [93] and CASP5 (caspase 5) [94]. The most
common mutations in the MMR system itself are MLH1, MSH2 and
MSH6 mutations. Additionally, frame shift mutations are also
observed in a selective number of microsatellites (BAT25, BAT26,
D5S346, D2S123 and D17S250) [95]. A classic example of the MSI
etiology is Hereditary Nonpolyposis Colorectal Cancer (HNPCC), in
which inherited mutations in the MMR system significantly increase
the risk of developing CRC [96].
CpG island methylator phenotype (CIMP) pathway: The CIMP
pathway is the most recent addition to the CRC etiologies [97]. While
CpG islands found in mammalian gene promoters are generally devoid
of methylation and result in constitutive transcription of the
accompanying genes [98], widespread methylation of CpG islands
occurs in CIMP, resulting in gene silencing [97]. Silencing of tumor
suppressor genes has been hypothesized as a hallmark in emergence of
CRC.
The extension of methylation of specific genes can further
distinguish between CIMP-high and CIMP-low specific loci [99].
Additionally, a CIMP-low region is associated with wild-type BRAF
and KRAS mutations and occurs more in men than in women [99]; by
contrast, the CIMP-high locus is associated with wild-type KRAS and
BRAF mutations, occurring more frequently in women than in men,
and is commonly associated with MSI [99,100]. The CIMP-high
pathway can give rise to the MSI pathway by AXIN2 methylation [83].
At least four loci can serve as sensitive and specific markers for CIMPhigh, these include RUNX3, CACNA1G, IGF2, and MLH1 [101]. The
probability that none of these four genes are methylated in CIMP-high
is less than 1% [101].
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